

Cochrane Nursing Care Field: Human albumin for intra-dialytic hypotension in haemodialysis patients

Lesley Andrews

Andrews L (2011). Cochrane Nursing Care Field: Human albumin for intra-dialytic hypotension in haemodialysis patients. *Ren Soc Aust J*, 7(3), 136–137.

Submitted September 2011 Accepted September 2011



Review question

What is the best available evidence on the safety and efficacy of using human albumin for the treatment of intra-dialytic hypotension (IDH) in haemodialysis patients?

Relevance for clinical practice

Hypotension is the most common intra-dialytic complication occurring in 20%–50% of the haemodialysis sessions (Irwin & Rippe, 2003). Despite the use of a variety of preventative measures, such as sodium profiling, sequential ultrafiltration and prescription dialysate, some patients still experience the adverse effects of a sudden drop in blood pressure (BP). The main cause of this unpleasant complication is fluid removal during the dialysis procedure, although other factors are also known to contribute, for example the components of the dialysis procedure and other patient-specific factors such as left ventricular dysfunction.

The primary mode of treatment is to replace fluids as a means of increasing the circulating blood volume. While fluid replacement can have favourable short-term results in correcting the

hypotension and relieving the symptoms, the long-term effects can cause more serious complications such as cardiac or cerebral ischaemia. Several fluids can be used for this purpose such as saline, human albumin, gelatin or starches. The use of albumin as a replacement fluid is controversial, mainly due to the cost implications as well as the potential for transmission of blood-borne viral disease such as Creutzfeldt-Jacob Disease (CJD).

Nurses need to be aware of the benefits and risks associated with the fluids they are using for treatment to enable them to make informed choices when selecting a fluid for the correction of IDH. This is especially true where there is an increased potential for hypotension during haemodialysis associated with increasing age and comorbid conditions of future dialysis patients.

This review was performed to determine if albumin provides a therapeutic advantage over other fluids in the treatment of hypotension during dialysis.

Characteristics of the evidence

The search focused on randomised, controlled trials (RCTs), quasi-RCTs and randomised, crossover studies

Keywords

Systematic review, hypotension, haemodialysis, albumin, safety, efficacy.

investigating the use of human albumin, alone or in combination with other fluids for treatment of IDH in maintenance haemodialysis patients. There was a requirement that all participants be adults undergoing long-term haemodialysis and experiencing episodes of systematic IDH. IDH was defined as a decrease in systolic BP of at least 10 mmHg or a systolic BP less than 100 mmHg with symptoms such as cramps, nausea, vomiting and dizziness.

One study met the inclusion criteria for the review, which compared albumin to normal saline; no other trials were identified that compared albumin with any other fluid. Adults who received haemodialysis treatments for a minimum period of three months and who had experienced at least three episodes of IDH in the 60-day period leading up to enrolment into the study were included. Patients were excluded if they were known to have sensitivity to albumin.

This was a well-conducted trial involving 45 patients arranged into evenly balanced

Author details: Ms Lesley Andrews is a Teaching Fellow in the School of Nursing, Midwifery and Health at the University of Stirling, Scotland, UK.

Correspondence to: lesley.andrews@stir.ac.uk

Cochrane Nursing Care Field: Human albumin for intra-dialytic hypotension in haemodialysis patients

groups, randomised to two treatment sequences. Sequence one patients received 5% albumin to treat the first episode of IDH, with the second and third episodes of IDH treated with normal saline. Patients in sequence two received normal saline to treat the first episode of IDH, with the second and third episodes of IDH treated with 5% albumin.

The primary outcome measure was the percentage of the target ultrafiltration achieved. The secondary outcome measures were post-dialysis systolic and diastolic BP, volume of study fluid used, time to restore BP and total nursing time to treat hypotensive episodes. The results of this trial showed no significant difference between albumin and saline in the percentage of target ultrafiltration achieved.

In summary, the study showed that 5% albumin is not superior to normal saline for the treatment of symptomatic hypotension in maintenance haemodialysis patients with a history of IDH.

Implications for clinical practice

There is insufficient evidence to support the therapeutic advantage that albumin has over crystalloids or non-protein colloids for the treatment of symptomatic hypotension during haemodialysis

The evidence suggests that there is no significant clinical benefit of using 5% albumin over normal saline; therefore, saline should be the first-line treatment of IDH in stable dialysis patients.

Implications for research

Further studies are required comparing albumin to crystalloids or non-protein crystalloids for the prophylactic maintenance of blood value and BP

during haemodialysis for patients at risk of hypotension.

There is a need to compare the efficiency of non-protein colloids such as pentastarch versus albumin for the treatment of IDH.

Reference

Fortin PM, Bassett K & Musini VM (2010).

Human albumin for intra-dialytic hypotension in haemodialysis patients.

Cochrane Database of Systematic Reviews, Issue 11, Art. No.: CD006758, DOI: 10.1002/14651858.CD006758.pub2.

Irwin RS & Rippe JM (eds) (2003). *Irwin and Rippe's intensive care medicine* (5th edn). Philadelphia: Lippincott, Williams and Wilkins.



The poster for the RSA 2012 conference features a central graphic of a kidney composed of many colorful hands reaching towards it. To the left is a circular logo celebrating 40 years of the RSA. The top right corner shows a large, faint hand graphic. The bottom of the poster is decorated with a city skyline at night and more colorful hands.

RSA 2012
Celebrating our Culture and Diversity in Renal Care
6–9 June 2012
The Sebel Albert Park Melbourne

MELBOURNE, AUSTRALIA www.rsa2012.org

On behalf of the Victorian Organising Committee we invite you to join us in Melbourne for the 40th Annual Renal Society of Australasia Conference in June 2012.

Melbourne boasts great events, a passion for food and wine and a fabulous arts scene. Known as a style-setter, Melbourne is home to a non-stop program of festivals, renowned dining, major art exhibitions and musical extravaganzas and is known as the cultural capital of Australia.

The theme for the conference, *Celebrating our Culture and Diversity in Renal Care* offers an opportunity to bring together novices, practitioners, researchers and experts to share knowledge, innovation, experience and expertise.

The conference will be held at The Sebel Albert Park Melbourne. This venue is centrally located on Queens Road, minutes from Melbourne's central business district and St Kilda Road. The hotel overlooks picturesque Albert Park Lake. So come along and help us celebrate the RSA's 40th birthday party.

We encourage everybody to take up the challenge and submit an abstract and share the rewarding experience of participating at the conference. We look forward to seeing you in Melbourne in 2012.

Jenny Beavis
Convenor RSA 2012

KEY DATES

Call for Abstracts Open	5 September 2011
Registration Open	7 December 2011
Call for Abstracts Close	30 January 2012
Author Notification	23 March 2012
Author Acceptance Close	13 April 2012
Early Bird Close	13 April 2012

WHO SHOULD ATTEND?

- Nurses
- Transplant coordinators
- Pharmacists
- Dieticians
- Social Workers
- Educators
- Technicians
- Researchers
- Healthcare professionals working with people who have kidney disease

arinex RSA 2012 Conference Managers
91–97 Islington Street Collingwood VIC 3066 AUSTRALIA
P: +61 3 9417 0888 F: +61 3 9417 0899 E: rsa2012@arinex.com.au
W: www.rsa2012.org